Alosetron: a case study in regulatory capture, or a victory for patients' rights?
- PMID: 12228140
- PMCID: PMC1124108
- DOI: 10.1136/bmj.325.7364.592
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
Figures
Comment in
-
Alosetron for irritable bowel syndrome.BMJ. 2002 Sep 14;325(7364):555-6. doi: 10.1136/bmj.325.7364.555. BMJ. 2002. PMID: 12228116 Free PMC article. No abstract available.
-
Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.BMJ. 2003 Jan 4;326(7379):51. BMJ. 2003. PMID: 12511473 No abstract available.
-
Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.BMJ. 2003 Jan 4;326(7379):51. BMJ. 2003. PMID: 12518769 No abstract available.
References
-
- Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet. 2000;357:1544–1545. - PubMed
-
- Public Citizen. Problems in the new drug approval process: a case study of Lotronex. www.citizen.org/congress/regulations/issue_areas/drug_devise/articles.cf... (accessed 30 Aug 2002).
-
- Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Gastrointestinal Drugs Advisory Committee, 16 November 1999. www.fda.gov/ohrms/dockets/ac/99/transcpt/3565t1a.pdf (accessed 30 Aug 2002).
-
- Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Gastrointestinal Drugs Advisory Committee, 27 June 2000. www.fda.gov/ohrms/dockets/ac/00/transcripts/3627t2.rtf (accessed 30 Aug 2002).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical